Peter Barnes FRS, FPM Council Member, has been Margaret Turner-Warwick Professor of Medicine at the National Heart and Lung Institute and Honorary Consultant Physician at Royal Brompton Hospital, London since 1987. His research is focused on cellular and molecular mechanisms of asthma and COPD, understanding and developing therapies and research into biomarkers for these diseases. He is involved in multidisciplinary translational research which integrates basic science with clinical studies, thereby providing novel insights into common airway diseases. He qualified at Cambridge and Oxford Universities (first class honours). He has published over 1000 peer-review papers on asthma, COPD and related topics and has edited over 40 books (h-index = 153). He is also amongst the top 50 most highly cited researchers in the world and has been the most highly cited clinical scientist in the UK and the most highly cited respiratory researcher in the world over the last 20 years. He was elected a Fellow of the Royal Society in 2007, the first respiratory researcher for over 150 years. He has been a member of the Scientific Committee of global guidelines on asthma (GINA) and COPD (GOLD). He also serves on the Editorial Board of over 30 journals and is currently an Associate Editor of Chest, Journal of COPD Foundation, Respiratory Editor of PLoS Medicine and Editor in Chief of Up-to-Date Pulmonary Diseases. He has given several prestigious lectures, including the Amberson Lecture at the American Thoracic Society, the Sadoul Lecture at the European Respiratory Society and the Croonian Lecture at the Royal College of Physicians. He has received honorary MD degrees from the Universities of Ferrara (Italy), Athens (Greece), Tampere (Finland) and Leuven (Belgium). He is an Emeritus NIHR Senior Investigator, a Master Fellow of the American College of Chest Physicians and a member of the Academia Europaea. He was President of the European Respiratory Society 2013/14. He co-founded Imperial spin-out company RespiVert, which was acquired by Johnson & Johnson and has developed novel inhaled treatments for COPD and severe asthma.
Professor Donald Singer @HealthMed is President of the FPM. He is a Clinical Pharmacologist interested in new approaches to personalising medicine and in public understanding of health and drugs. He is a member of the panel of experts of the European Medicines Agency. A member since 2013 of the Healthcare Professionals’ Working Party of the European Medicines Agency, he is involved in current EMA projects on minimizing risk from medicines. International consultancy includes advice on clinical pharmacology and safety systems for medicines as a Yale School of Medicine Faculty member within the 7 year Human Resources for Health US-AID and CDC supported programme in Rwanda. Singer is President of the UK Fellowship of Postgraduate Medicine, which publishes the Postgraduate Medical Journal (founded 1925) and Health Policy and Technology (founded 2012). He is a former Secretary of the European Association of Clinical Pharmacology and Therapeutics which supports scientific and educational exchange for over 4000 clinical pharmacologists from 34 countries. He was previously also a member of the Council of the British Pharmacological Society and Panel Member of the NIHR Health Technology Assessment Programme.